Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Internal Medicine

Cardiology

Surgery

Cardiology And Cardiovascular Medicine

Show all topics

DOI

10.1016/s0140-6736(15)00447-x

Other Formats

PDF